2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private PlacementPsyched Wellness Commences Pre-Clinical Trials of Amanita MuscariaHavn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an

Join the top platform for cannabis stock analysis.

Premium Newsletter & Content Feed

A daily stream of market moving news, company announcements and earnings announcements keeps your finger on the pulse of the market.

Priority Access to Our Analysts

Have an urgent question on a stock, company, or trade? As a premium member, you have direct, priority access to our team.

Member’s Dashboard

Everything you need in one convenient, sleek dashboard. Access your premium news, market data, exclusive Mushroomstocks reports, and more.

What Members are Saying:

  • “In the crazy world of cannabis stocks, I’ve found Techincal420’s advice knowledge and invaluable. Techincal420’s team does a great job researching companies which helps me concentrate on the right companies. ” PAUL
  • “I read about technical 420 a couple months ago on a CNBC article… I was thrilled about Michael Berger’s idea of covering this seed-stage market since day one. Personally, I think the article undersold the value that Michael provides his subscribers. Michael is able to find value in an opaque market and rely that information in a way that is easy to understand and act on. If you want to invest in cannabis stocks, Mushroomstocks is the place to go!” ERALDO
  • “I want to thank Michael Berger for creating this resource. Similarly, I asked my Raymond James investment advisor about resources for investing in the Cannabis industry. I was given this website, among others. Out of all the resources I was given, Mushroomstocks without a doubt provides the most thorough and non-biased information on marijuana stocks and the cannabis industry. ” KAI
  • “Michael is a wiz when it comes to the stock market. I came to Mushroomstocks without any investment experience and Michael essentially tutored me and explained how everything works and why it works in the fashion it does. When it comes to the marijuana industry there is no one better. His cutting edge approach to this promising, yet opaque market is second to none. I would unquestionably recommend him to anyone who wants to learn about the marijuana stock industry.” NIMZJAB

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link